Not yet recruiting
A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.
NCT07729033· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Huikai Li
Recruiting
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587· Phase 1· Shanghai Henlius Biotech· Source
Contact: Yinping Zhong
Recruiting
IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus
NCT07799922· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Li Huikai, MD
Recruiting
IRE After Chemotherapy for Locally Advanced Pancreatic Cancer
NCT07799935· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Li Huikai, MD
Recruiting
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
NCT07528274· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Tongguo Si, MD. Ph.D
Recruiting
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
NCT07479485· Phase 1/2· Lepu Biopharma Co., Ltd.· Source
Contact: Huikai Li
Recruiting
HCCANANO-HOPE1: IRE After Chemotherapy for Locally Advanced Unresectable Perihilar Cholangiocarcinoma
NCT07795619· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Li Huikai, MD
Recruiting
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
NCT07560488· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Huikai Li, Prof.
Not yet recruiting
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
NCT07187960· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Yafei Wang, Doctor
Recruiting
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
NCT07012798· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Li Huikai, MD
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Chunfang Hao, Site 1027
Recruiting
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT07169994· Phase 1/2· MediLink Therapeutics (Suzhou) Co., Ltd.· Source
Contact: Study Coordinator
Not yet recruiting
Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
NCT07139470· Phase 1/2· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Chunfang Hao
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601· Phase 1· Eli Lilly and Company· Source
Not yet recruiting
RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
NCT07114432· Phase 1· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Yafei Wang, PhD
Recruiting
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
NCT07047365· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Chunfang Hao, Doctor
Recruiting
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
NCT07003074· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Chunfang Hao, Doctor
Recruiting
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034· Phase 2· Abbisko Therapeutics Co, Ltd· Source
Contact: Tongguo Si
Not yet recruiting
Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies
NCT06993025· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Lu chen, MD
Recruiting
A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer
NCT06970119· Phase 1/2· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source
Contact: Dong Dai, Doctor of Medicine (M.D.)
Recruiting
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
NCT06860971· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Wenchao Zhang, Doctor
Active, not recruiting
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
NCT06900543· Phase 3· Chengdu New Radiomedicine Technology Co. LTD.· Source
Recruiting
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
NCT06821503· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Huikai Li, Doctor
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· Phase 3· Hoffmann-La Roche· Source
Not yet recruiting
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
NCT06922903· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source
Contact: Dong Yuan
Not yet recruiting
A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
NCT06922929· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source
Contact: Dong Yuan
Recruiting
A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
NCT06944106· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Li Huikai, MD
Recruiting
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
NCT06878625· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Chunfang Hao, Associate chief physician
Recruiting
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
NCT06750419· Phase 3· Telix Pharmaceuticals (Innovations) Pty Limited· Source
Contact: Dong Dai
Recruiting
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
NCT06361888· Phase 2/3· Hutchmed· Source
Contact: Huikai Li
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776· Daiichi Sankyo· Source
Contact: Principal Investigator
Recruiting
Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
NCT06139575· Phase 1/2· Bivision Pharmaceuticals, Inc.· Source
Contact: Bivision Pharmaceuticals, Inc.
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· Phase 3· LeonaBio· Source
Contact: Chunfang Hao
Recruiting
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
NCT05862337· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Huikai Li, Doctor
Active, not recruiting
Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study
NCT05685550· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source
Active, not recruiting
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906· Phase 3· Bayer· Source
Recruiting
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
NCT05640791· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Huikai Li, MD
Active, not recruiting
A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma
NCT05644379· Phase 1· Tianjin Medical University Cancer Institute and Hospital· Source
Recruiting
Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC
NCT05446467· Phase 2· Zhejiang Provincial People's Hospital· Source
Contact: Wenchao Zhang
Active, not recruiting
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer
NCT05195632· Phase 2· Pierre Fabre Medicament· Source